Investor Presentation on financial results for the first quarter ended June 30, 2026 is attached.

A a C U T fi A S® ACUTAAS CHEMICALS LIMITED (Formerly known as Ami Organics Lirnited) CIN No. : L24100GJ2007PLCO51093 You and us: chemistry’s apex July 24, 2026 To, To, The Listing Department, The Listing Department BSE LIMITED, National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5% Floor, Plot No. C-1, Dalal Street, Fort G-Block, Bandra Kurla Complex, Mumbai- 400 001 Mumbai -400051 Scrip Code: 543349 NSE Symbol: ACUTAAS Subject: Investor Presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on financial results for the first quarter ended as on June 30, 2026 and other business matters. This Investor Presentation will also be available on the website of the Company www.acutaas.com. Kindly take the same on record. Yours faithfully, For, ACUTAAS CHEMICALS L'MITED Ekta Kumari Srivastava Company Secretary & Compliance Officer Encl: Presentation . +9175730 156366, +91 72279 77744 @ Registered Office: Plot No. 440/4, 5 & 6, 2 info@acutaas.com Road No. 82/A, GIDC Sachin, #: www.acutaas.com Dist. Surat- 394230, Gujarat, India E A R N I N G S P R E S E N T A T I O N JULY 2 0 2 6 www.acutaas.com www.acutaas.com Management Commentary (Mn.) Mr. Naresh Patel Revenue for Q1 FY27 ₹3,297 Executive Chairman and Managing Director “We have started the year on a strong note, with revenue from YoY ▲ operations growing 59.1% YoY to Rs. 3,297 mn — reflecting the 59.1% agility of our business model and our ability to keep delivering to customers, on time and without compromise. EBITDA for Q1 FY27 We have also been certified as a Great Place to Work — a ₹1,131 recognition of the culture of trust, collaboration and pride our people have built, and a proud validation of the team behind all we YoY ▲ have achieved. 122.1% We have further received the Responsible Care certification from the Indian Chemical Council — the industry’s commitment to the PAT for Q1 FY27 highest standards of safety, health and environmental ₹750 performance — reaffirming our resolve to grow responsibly and sustainably. YoY ▲ Overall, we remain confident of delivering 25% revenue growth for 70.4% the full year with stable margins.” Earnings Presentation |July 2026 2 Q1 FY27 Financial Performance – Key Metrics Revenue from Operations (₹ Mn.) Q1 FY27 Earnings & Business Highlights YoY Growth 76.5% (10.6%) 59.1% 3,297 Pharma Intermediates 2,927 CDMO continues strong growth momentum; 2,072 Core Advanced intermediate business delivered 1,658 robust growth 414 370 Specialty Chemicals Strong growth in BFC offset by muted Advance Intermediates Specialty Chemicals Total performance in commodity chemicals Q1FY26 Q1FY27 EBITDA & EBITDA Margin PAT (₹ Mn) (₹ Mn.) EBITDA Margins 22.7% 34.3% Driven by better product mix and operational efficiencies 24.6% 21.2% PAT Margin PAT margins were driven by strong EBITDA 509 1,131 440 750 margins which was offset by lower other income Q1FY26 Q1FY27 Q1FY27 Q1FY27 EBITDA EBITDA Margin PAT PAT Margin Earnings Presentation | July 2026 3 Q1 FY27 Financial Performance – P&L Statement Particulars (Rs. Mn) Q1FY27 Q1FY26 YoY Q4FY26 QoQ Revenue from Operations 3,297 2,072 59.1% 4,328 -23.8% COGS 1,388 969 1,644 Gross Profit 1,909 1,103 73.0% 2,683 -28.8% Gross Margin 57.9% 53.2% 62.0% Employee Benefits Expenses 396 251 333 Other Expenses 383 344 515 Total Expenses 778 595 31.0% 848 -8.2% EBITDA 1,131 509 122.1% 1,835 -38.4% EBITDA Margin 34.3% 24.6% 42.4% Depreciation and amortization 98 81 96 PBIT 1,032 428 141.4% 1,739 -40.6% Finance costs 11 6 12 Other Income 18 159 111 PBT 1,039 581 78.9% 1,838 -43.5% Tax Expense 289 141 495 PAT 750 440 70.4% 1,343 -44.2% PAT Margin 22.7% 21.2% 31.0% Earnings Presentation | July 2026 4 Financial Performance over the years – Key Metrics Revenue from Operations- Growth Trends (₹ Mn.) EBITDA and EBITDA Margins (₹ Mn. & %) EBITDA (₹ Mn) EBITDA Margin (%) FY20-25 CAGR: 31.0% 67.8% 33.2% 35.9% FY20 FY21 FY22 FY23 FY24 FY25 FY26 13,394 0 11,741 23.0% 3 ,2 0 7 2 0 8 1 ,5 8 7 6 ,5 4 5 ,8 ,1 1,652 3 ,2 1 0 2 ,5 0 7 1 ,6 5 7 1 ,7 9 6 0 17.1% 23.5% 20.2% 19.9% 17.9% 7 1 410 802 1,052 1,227 1,285 2,321 4,804 Advance Intermediates Chemicals Total FY20 FY21 FY22 FY23 FY24 FY25 FY26 Revenue – by Business Verticals (%) Returns Profile# (%) PAT and PAT Margins (₹ Mn & %) Pharma Intermediates Specialty Chemicals ROCE ROE PAT (₹ Mn) PAT Margin (%) 26.6% 50.0% 1% 3% 5% 39.3% 45.0% 18% 16% 21% 15% 12% 40.0% 15.9% 30.7% 27.2% 35.0% 15.9% 32.4% 19.2% 19.7% 19.1% 32.5%30.0% 11.5% 13.8% 13.5% 11.3% 99% 97% 95% 25.0% 83% 84% 79% 85% 88% 24.6% 12.6% 20.0% 18.7% 15.0% 13.8% 15.1% 10.0% 11.4% 275 540 719 833 808 1,604 3,564 5.0% 0.0% FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 FY20 FY21 FY22 FY23 FY24 FY25 FY26 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Note: PAT for FY24 is adjusted for Exceptional Items # ROE and ROCE adjusted for Cash & Cash Equivalents, Exceptional Items, CWIP Earnings Presentation | July 2026 5 Financial Performance over the years - Profit and Loss Particulars (₹ Mn.) FY21 FY22 FY23 FY24 FY25 FY26 Revenue from Operations 3,406 5,201 6,167 7,175 10,069 13,394 Other Income 14 28 43 75 169 416 Total Income 3,420 5,229 6,210 7,250 10,238 13,810 Cost of materials consumed 1,749 2,823 3,459 4,402 5,698 5,950 Changes in Inventories¹ 48 (95) (150) (285) (176) (290) Employee benefits expenses 210 414 488 631 837 1,176 Finance cost 56 64 24 59 62 33 Depreciation and amortisation expenses 42 101 123 161 266 360 Other expenses 598 1,008 1,144 1,142 1,390 1,754 Total Expense 2,703 4,315 5,088 6,110 8,077 8,982 Profit before tax and exceptional items 717 914 1,122 1,140 2,162 4,827 Exceptional profit / (loss) - - - (321) - - Tax expense 177 195 289 332 557 1,264 Profit for the year 540 719 833 487 1,604 3,564 Earnings Presentation | July 2026 6 ¹ Changes in inventories of finished goods, traded goods and work-in-progress Financial Performance over the years - Balance Sheet Assets (₹ Mn.) FY21 FY22 FY23 FY24 FY25 FY26 Liabilities & Equity (₹ Mn.) FY21 FY22 FY23 FY24 FY25 FY26 Property, plant and 1,422 1,584 1,844 3,229 4,629 5,828 Shareholder's equity 1,669 5,223 5,939 6,828 13,201 17,108 equipment Right of use assets 184 194 374 372 424 505 Financial Liabilities 726 6 6 1,136 48 91 Capital work-in-progress 2 30 255 1,254 1,303 3,324 Provisions 44 4 7 13 25 46 Goodwill - - 203 568 568 1,043 Other intangible assets 257 267 211 103 83 72 Deferred tax liabilities (net) 33 63 88 130 196 287 Investments 14 17 17 2 2 2 Total non-current liabilities 803 73 101 1,280 269 424 Other financial assets 27 108 65 26 49 82 Current tax assets (net) - 49 32 25 2 - Borrowings 640 3 30 1,030 82 265 Other non-current assets 64 97 129 447 517 171 Trade payables 848 1,184 1420 1,346 1,561 1,539 Total non-current assets 1,970 2,346 3,130 6,026 7,577 11,027 Other current liabilities 151 46 64 344 135 124 Inventories 604 1,122 1,192 1,567 1,799 2,313 Trade receivables 1,207 1,637 2,303 2,064 2,905 3,626 Provisions 10 60 114 132 245 325 Cash and cash equivalents 27 103 305 297 1,852 2,156 Current tax liabilities (net) 11 - - - - 55 Other bank balances - 893 281 236 637 93 Loans 3 6 13 16 22 26 Total current liabilities 1,660 1,293 1,628 2,852 2,023 2,308 Other current assets 321 481 445 753 701 599 Total liabilities 2,463 1,366 1,730 4,131 2,292 2,732 Total current assets 2,162 4,291 4,571 4,958 7,916 8,813 Total equity and liabilities 4,133 6,589 7,669 10,959 15,493 19,840 Total assets 4,133 6,589 7,669 10,959 15,493 19,840 Earnings Presentation | July 2026 7 Shareholder Information Shareholding as on 30th June 2026 Share Information as on 30th June 2026 Others Promoters NSE Ticker ACUTAAS 26.2% 32.7% BSE Ticker 543349 Market Cap (₹ Cr.) 28,869 Shares Outstanding 8,18,71,122 3M ADTV (Shares) 4,86,444 3M ADTV (₹ Cr.) 82.4 14.2% 21 [Showing first 8,000 characters — download PDF for full document]